Therapeutic suppressor tRNAs are engineered to broaden their target range in vivo.

Engineered bacteria sense gut bleeding and secrete repair materials.

CONCORD generates denoised cell encodings that preserve key biological structures in single-cell datasets.

Differential isoform usage is identified with high statistical power from spatial transcriptomics data.

Cas3 nuclease is used for therapeutic deletion of a gene in mice.

Engineered inhalable exosomes deliver a bispecific T cell activator to pembrolizumab-resistant metastatic melanoma.

Immunotherapy is at an inflection point. After three decades of accelerating progress, immunotherapy is entering the realm of in vivo engineering. This Comment discusses the potential of in vivo engineering in addressing challenges met by ex vivo engineering efforts. Per a recent workshop organized by the National Institutes of Health, we highlight progress, the platform technologies fueling it, and elements of a road map and challenges ahead.

Leadership changes, staff cuts and a raft of new policies marked an agency in transition. New drug approvals featured more follow-on products than firsts.